Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Eczema

Interventions: Drug: Placebo
Drug: Lebrikizumab
Drug: Topical Corticosteroid

First Posted Date: 2021-02-18

Last Posted Date: 2023-08-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 286

Registration Number: NCT04760314

Locations: 🇯🇵
Hiroshima University Hospital, Hiroshima-shi, Hiroshima-ken, Japan
🇯🇵
KAJI Dermatology Clinic, Nonoichi-shi, Ishikawa, Japan
🇯🇵
Kosugi Dermatology Clinic, Kawasaki, Kanagawa, Japan

and more 34 locations

A Study of LY3549492 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3549492
Drug: Placebo

First Posted Date: 2021-02-17

Last Posted Date: 2022-02-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 54

Registration Number: NCT04758234

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Phase 3

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Abemaciclib
Drug: Standard Adjuvant ET
Drug: Placebo

First Posted Date: 2021-02-12

Last Posted Date: 2024-07-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 111

Registration Number: NCT04752332

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Hainan Cancer Hospital, Haikou, Hainan, China
🇨🇳
Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 111 locations

A Study of Lasmiditan in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lasmiditan
Drug: Rosuvastatin
Drug: Dabigatran Etexilate

First Posted Date: 2021-02-11

Last Posted Date: 2024-02-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 97

Registration Number: NCT04749914

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain

Phase 2

Terminated

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: LY3556050
Drug: Placebo

First Posted Date: 2021-01-13

Last Posted Date: 2023-11-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 68

Registration Number: NCT04707157

Locations: 🇺🇸
Alliance for Multispecialty Research - Clinical Research Consortium, Tempe, Arizona, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
NorthShore University HealthSystem, Skokie, Illinois, United States

and more 31 locations

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

Phase 4

Completed

Conditions: Neoplasm Metastasis
Breast Neoplasms

Interventions: Drug: Abemaciclib
Drug: Nonsteroidal Aromatase Inhibitor (NSAI)
Drug: Fulvestrant

First Posted Date: 2021-01-13

Last Posted Date: 2023-11-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 200

Registration Number: NCT04707196

Locations: 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳
Meditrina Institute of Medical Sciences, Nagpur, Maharashtra, India
🇮🇳
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India

and more 12 locations

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Bamlanivimab

First Posted Date: 2021-01-08

Last Posted Date: 2021-11-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 109

Registration Number: NCT04701658

Locations: 🇺🇸
Presbyterian Medical Center, Albuquerque, New Mexico, United States

A Study of LY3502970 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3502970
Drug: [¹⁴C]-LY3502970

First Posted Date: 2020-12-23

Last Posted Date: 2021-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT04680767

Locations: 🇬🇧
Covance Clinical Research, Leeds, United Kingdom

A Safety Study of LY3526318 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3526318
Drug: Placebo

First Posted Date: 2020-12-23

Last Posted Date: 2021-06-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT04682119

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study of Continuous Heart Rate Monitoring in Healthy Participants

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Propranolol
Drug: Pseudoephedrine
Device: Wearable Biosensor Patch Device

First Posted Date: 2020-12-23

Last Posted Date: 2021-04-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 21

Registration Number: NCT04682184

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy